Brandenburg Kapital - News about Pentracor GmbH

Hennigsdorf/Berlin - December 2020. Pentracor GmbH, a private equity firm from the Brandenburg Kapital portfolio since 2011, congratulates its long-standing partner on the German Medical Award, which was awarded in November.

The company is delighted that Prof. Jan Torzewski of the Klinikum Kempten, a long-time user of CRP apheresis, has won second place in the category "Cardiology- Medical Innovation Practices & Clinics" at the German Medical Award. The competition is the leading event for medicine and medical management in the German-speaking world.

The first place was awarded to Prof. Dr. Sebastian Kelle of the Cardiac MRI Core Lab at the German Heart Center in Berlin, with whom Pentracor is also scientifically linked in the context of the CAM11 study.

Pentracor produces and markets a specific adsorber for the therapeutic lowering of C-reactive protein (CRP) from the blood plasma of heart attack patients to reduce damage to the heart. With CRP apheresis and the PentraSorb® filter product, it is pursuing a new approach in the acute treatment of heart attacks to minimize subsequent damage. Today, several hospitals in Germany are already successfully using CRP apheresis.

Click here for the full message: Pentracor Website - News

For more information, see www.brandenburg-kapital.de and www.pentracor.de